TY - JOUR T1 - Genome-wide association studies of <em>LRRK2</em> modifiers of Parkinson’s disease JF - medRxiv DO - 10.1101/2020.12.14.20224378 SP - 2020.12.14.20224378 AU - Dongbing Lai AU - Babak Alipanahi AU - Pierre Fontanillas AU - Tae-Hwi Schwantes-An AU - Jan Aasly AU - Roy N. Alcalay AU - Gary W. Beecham AU - Daniela Berg AU - Susan Bressman AU - Alexis Brice AU - Kathrin Brockman AU - Lorraine Clark AU - Mark Cookson AU - Sayantan Das AU - Vivianna Van Deerlin AU - Matthew Farrer AU - Joanne Trinh AU - Thomas Gasser AU - Stefano Goldwurm AU - Emil Gustavsson AU - Christine Klein AU - Anthony E. Lang AU - J. William Langston AU - Jeanne Latourelle AU - Timothy Lynch AU - Karen Marder AU - Connie Marras AU - Eden R. Martin AU - Cory Y. McLean AU - Helen Mejia-Santana AU - Eric Molho AU - Richard H. Myers AU - Karen Nuytemans AU - Laurie Ozelius AU - Haydeh Payami AU - Deborah Raymond AU - Ekaterina Rogaeva AU - Michael P. Rogers AU - Owen A. Ross AU - Ali Samii AU - Rachel Saunders-Pullman AU - Birgitt Schüle AU - Claudia Schulte AU - William K. Scott AU - Caroline Tanner AU - Eduardo Tolosa AU - James E. Tomkins AU - Dolores Vilas AU - John Q. Trojanowski AU - The 23andMe Research Team AU - Ryan Uitti AU - Jeffery M. Vance AU - Naomi P. Visanji AU - Zbigniew K. Wszolek AU - Cyrus P. Zabetian AU - Anat Mirelman AU - Nir Giladi AU - Avi Orr Urtreger AU - Paul Cannon AU - Brian Fiske AU - Tatiana Foroud Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/16/2020.12.14.20224378.abstract N2 - Objective The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age-at-onset of Parkinson’s disease.Methods We performed the first genome-wide association study of penetrance and age-at-onset of Parkinson’s disease in LRRK2 mutation carriers (776 cases and 1,103 non-cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age-at-onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genome-wide association study of Parkinson’s disease was able to explain variability in penetrance and age-at-onset in LRRK2 mutation carriers.Results A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; P-value=2.5E-08, beta=1.27, SE=0.23, risk allele: C) met genome-wide significance for the penetrance model. A region on chromosome 3, within a previously reported linkage peak for Parkinson’s disease susceptibility, showed suggestive associations in both models (penetrance top variant: P-value=1.1E-07; age-at-onset top variant: P-value=9.3E-07). A polygenic risk score derived from publicly available Parkinson’s disease summary statistics was a significant predictor of penetrance, but not of age-at-onset.Interpretation This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson’s disease associated variants collectively increase the penetrance of LRRK2 mutations.Competing Interest StatementB.A., P.F., P.C., S.D., C.Y.M., and members of the 23andMe Research Team are current or former employees of 23andMe, Inc., and hold stock or stock options in 23andMe. Funding StatementThis work is supported by The Michael J. Fox Foundation for Parkinson's Research Grants 7984, 7984.01, 7984.02 and 8981. Enrollment and clinical characterization of participants was in part funded by grants from the NIH (R01 NS065070, P50 NS062684) and the Department of Veterans Affairs (5I01CX001702). The cohort from Columbia University, New York, NY, was funded by the Parkinson's Foundation, the NIH (K02NS080915 and UL1 TR000040), and the Brookdale Foundation. The Mayo Clinic was a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS P50 NS072187) and is an American Parkinson Disease Association Information and Referral Center. This study at the Mayo Clinic was also partially funded by the gifts from The Sol Goldman Charitable Trust, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. This work was supported in part by NINDS R01-NS078086, NINDS Tau Center without Walls (U54-NS100693 and U54- NS110435), DOD award (W81XWH-17-1-0249), The Michael J. Fox Foundation, the Little Family Foundation, the Functional Genomics of LBD Program, the Mangurian Foundation Lewy Body Dementia Program at Mayo Clinic and Mayo Clinic Center for Individualized Medicine. The University of Miami Parkinson disease research group was a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS P50 NS039764 and NS071674). Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268201200008I. R.N.A received research funding from the NIH, the Parkinson's Foundation, and The Michael J. Fox Foundation. V.V.D is supported by NS053488, AG010124, and AG062418. T.F is supported by R01NS096740 and The Michael J. Fox Foundation. C.K. received funding from the DFG (FOR2488). E.M. is supported by the Riley Chair in Parkinson's Disease. K.M. is supported by NIH NS036630, UL1TR001873, the Parkinson's Disease Foundation, The Michael J. Fox Foundation. E.R. was in part supported by the Canadian Consortium on Neurodegeneration in Aging. J.Trojanowski. is supported by AG010124 and AG062418. J. Trinh. received research funding from the Canadian Institutes of Health Research, Else Kroener Fresenius Foundation and DFG (FOR2488). J.E.T. is supported by the 2019 Biomarkers Across Neurodegenerative Diseases Grant Program, BAND3 (Michael J Fox Foundation, Alzheimer's Association, Alzheimer's Research UK and Weston Brain Institute [grant number 18063]). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional review board at Indiana University; the Institutional Review Board (Helsinki) Committee of Tel Aviv Sourasky Medical Center and the National Helsinki Committee for Genetic Research in Humans, MINISTRY OF HEALTH, Israel; Ethical &amp; Independent Review Services, a private institutional review board (http://www.eandireview.com).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregate-level data included in this study will be made available to qualified investigators upon request. Investigators interested in receiving 23andMe data, either alone or in combination with data from other cohorts, will need to sign a Data Transfer Agreement with 23andMe that protects 23andMe research participant privacy, and should visit https://research.23andme.com/dataset-access/ to submit a request. ER -